ARMO ARMO BioSciences Inc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of ARMO BioSciences, Inc. to Eli Lilly is Fair to Shareholders

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased ARMO BioSciences, Inc. (“ARMO” or the “Company”) (NASDAQGS: ARMO) stock prior to May 10, 2018.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of ARMO to Eli Lilly and Company (NYSE: LLY) for $50 per share. To learn more about the action and your rights, go to:

http://www.zlk.com/mna/armo-biosciences-inc

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The investigation concerns whether the Board of ARMO breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Eli Lilly and Company is underpaying for ARMO shares, thus unlawfully harming ARMO shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
10/05/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ARMO BioSciences Inc

 PRESS RELEASE

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of...

NEW YORK--(BUSINESS WIRE)-- Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of ARMO BioSciences, Inc. (NASDAQ: ARMO) stockholders concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY). Our investigation concerns whether ARMO’s board of directors failed to adequately shop the Company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with Eli Lilly. Under the terms of the agreement, ARMO stockholders will receive $...

 PRESS RELEASE

ARMO BIOSCIENCES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Annou...

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of ARMO BioSciences, Inc. (NASDAQ GS: ARMO)? Did you purchase any of your shares prior to May 10, 2018? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of ARMO BioSciences, Inc. (“ARMO” or the “Company”) (NASDAQ GS: ARMO) regar...

 PRESS RELEASE

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Inve...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased ARMO BioSciences, Inc. (“ARMO” or the “Company”) (NASDAQGS: ARMO) stock prior to May 10, 2018. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of ARMO to Eli Lilly and Company (NYSE: LLY) for $50 per share. To learn more about the action and your rights, go to: http://www.zlk.com/mna/armo-biosciences-inc ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch